60.60
price down icon0.13%   -0.08
 
loading
前日終値:
$60.68
開ける:
$60.72
24時間の取引高:
1.20M
Relative Volume:
0.71
時価総額:
$11.74B
収益:
$4.08B
当期純損益:
$32.48M
株価収益率:
432.86
EPS:
0.14
ネットキャッシュフロー:
$16.80M
1週間 パフォーマンス:
-2.13%
1か月 パフォーマンス:
-17.19%
6か月 パフォーマンス:
-7.94%
1年 パフォーマンス:
+6.37%
1日の値動き範囲:
Value
$60.35
$60.97
1週間の範囲:
Value
$60.24
$63.31
52週間の値動き範囲:
Value
$50.35
$83.95

Incyte Corp Stock (INCY) Company Profile

Name
名前
Incyte Corp
Name
セクター
Healthcare (1166)
Name
電話
(302) 498-6700
Name
住所
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
職員
0
Name
Twitter
@Incyte
Name
次回の収益日
2025-02-10
Name
最新のSEC提出書
Name
INCY's Discussions on Twitter

INCY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INCY
Incyte Corp
60.60 11.74B 4.08B 32.48M 16.80M 0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Incyte Corp Stock (INCY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-18 ダウングレード Guggenheim Buy → Neutral
2025-03-18 ダウングレード William Blair Outperform → Mkt Perform
2024-12-17 開始されました UBS Neutral
2024-10-29 アップグレード BofA Securities Neutral → Buy
2024-10-01 開始されました Wolfe Research Outperform
2024-09-18 ダウングレード Truist Buy → Hold
2024-07-02 ダウングレード BMO Capital Markets Market Perform → Underperform
2024-05-23 開始されました Deutsche Bank Hold
2024-04-23 開始されました Cantor Fitzgerald Neutral
2024-02-23 開始されました Jefferies Buy
2024-02-14 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 アップグレード Leerink Partners Market Perform → Outperform
2023-12-04 アップグレード Guggenheim Neutral → Buy
2023-11-21 ダウングレード Goldman Buy → Neutral
2023-07-25 開始されました Citigroup Buy
2023-05-04 ダウングレード BofA Securities Buy → Neutral
2023-04-10 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-03-24 アップグレード SVB Securities Underperform → Market Perform
2023-01-31 開始されました Piper Sandler Overweight
2022-08-03 ダウングレード Evercore ISI Outperform → In-line
2022-08-03 ダウングレード Guggenheim Buy → Neutral
2022-07-28 開始されました Wells Fargo Equal Weight
2022-02-09 ダウングレード SVB Leerink Mkt Perform → Underperform
2022-01-18 アップグレード RBC Capital Mkts Sector Perform → Outperform
2021-11-19 開始されました BMO Capital Markets Market Perform
2021-07-20 アップグレード The Benchmark Company Hold → Buy
2021-02-10 ダウングレード SVB Leerink Mkt Perform → Underperform
2021-01-07 開始されました Truist Buy
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-06-16 開始されました The Benchmark Company Hold
2020-05-06 ダウングレード JP Morgan Overweight → Neutral
2020-04-29 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-04-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-24 再開されました William Blair Outperform
2020-03-13 アップグレード BofA/Merrill Neutral → Buy
2020-02-04 再開されました BofA/Merrill Neutral
2020-01-03 繰り返されました BMO Capital Markets Market Perform
2020-01-03 ダウングレード Mizuho Buy → Neutral
2020-01-02 ダウングレード Guggenheim Buy → Neutral
2019-10-03 開始されました Mizuho Buy
2019-09-12 開始されました BMO Capital Markets Market Perform
2019-09-05 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 再開されました Morgan Stanley Equal-Weight
2019-09-05 アップグレード Oppenheimer Perform → Outperform
2019-05-21 開始されました Credit Suisse Neutral
2019-05-03 ダウングレード Barclays Overweight → Equal Weight
2019-04-11 開始されました Stifel Hold
2019-04-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-01-24 アップグレード William Blair Mkt Perform → Outperform
すべてを表示

Incyte Corp (INCY) 最新ニュース

pulisher
Mar 27, 2025

Incyte Announces Positive Phase 3 Results for Hidradenitis Suppurativa Treatment - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Mar 26, 2025
pulisher
Mar 24, 2025

Incyte Had a Bad Week. Investors Are Used to It. - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Leerink Partners Adjusts Price Target on Incyte to $92 From $100, Maintains Outperform Rating - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

Incyte’s Hold Rating: Balancing Pipeline Challenges and Established Product Valuation - TipRanks

Mar 24, 2025
pulisher
Mar 22, 2025

Monday.com, Incyte, Lucid, Bloom, EQT: Trending by Analysts - TipRanks

Mar 22, 2025
pulisher
Mar 21, 2025

Why Incyte Stock Was Tanking This Week - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Incyte (INCY) Stock Declines Due to Clinical Trial Results - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Yahoo Finance

Mar 21, 2025
pulisher
Mar 19, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Stock market unimpressed by results for Incyte acne drug as share price drops 11% - delawarebusinessnow.com

Mar 19, 2025
pulisher
Mar 19, 2025

Incyte price target lowered to $72 from $74 at Truist - Yahoo Finance

Mar 19, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BMV:INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte EVP Barry Flannelly sells $1.34 million in stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (BIT:1INCY) - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib (NASDAQ:INCY) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Marginal Zone Lymphoma Pipeline 2025: MOA and ROA Insights, - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

INCY Stock Down on Disappointing Skin Disease Study Data - Yahoo Finance

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte stock price target cut to $72 at Truist Securities - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte’s JAK1 blocker meets goals in Phase III trials - The Pharma Letter

Mar 18, 2025
pulisher
Mar 18, 2025

Jefferies cuts Incyte stock price target to $75, keeps Buy rating - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Mizuho maintains Incyte stock with $77 target, Neutral rating - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte divulges new MRGPRX2 antagonists - BioWorld Online

Mar 18, 2025
pulisher
Mar 18, 2025

Citi maintains Buy on Incyte shares, reiterates $88 target - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair cuts Incyte stock rating post-trial results - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Guggenheim Downgrades Incyte to Neutral From Buy -March 18, 2025 at 06:41 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Analyst recommendations: Block, Incyte, Ralph Lauren, Five Below, Tesla... - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Deutsche Bank Adjusts Price Target on Incyte to $60 From $70, Keeps Hold Rating -March 18, 2025 at 05:50 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Jefferies Adjusts Price Target on Incyte to $75 From $81, Keeps Buy Rating -March 18, 2025 at 05:50 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Truist Securities Adjusts Price Target on Incyte to $72 From $74, Keeps Hold Rating -March 18, 2025 at 05:45 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Incyte Corporation (INCY): Among the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

William Blair Downgrades Incyte (INCY) to Market Perform - StreetInsider.com

Mar 18, 2025
pulisher
Mar 17, 2025

Incyte stock dives after drug trial disappoints investors - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch

Mar 17, 2025
pulisher
Mar 17, 2025

RBC maintains Incyte stock with $68 target post-data release By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock tumbles despite meeting main goal in skin disease treatment trial - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte (INCY) Stock Drops on Phase Three Trial Data - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Why Incyte (INCY) Stock Is Nosediving - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Leerink says Incyte’s povo trial results disappoint, drug likely to be approved - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Oil pressures, Robinhood, Incyte: Market Minute - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Top Midday Decliners -March 17, 2025 at 02:00 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Reports Positive Results From Skin Therapy Study; Wells Fargo Cuts Price Target; Shares Drop - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Mizuho Reiterates Neutral Rating on Incyte (INCY) - StreetInsider.com

Mar 17, 2025
pulisher
Mar 17, 2025

US MARKET Live, 17 March 2025: Incyte Corp, Tesla, and Dollar General among top losers on S&P 500 - Moneycontrol

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock hit by 11% despite paediatric dermatology trials hitting target - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte stock hit 11% despite paediatric dermatology trials hitting target - Clinical Trials Arena

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Leads S&P 500 Decliners Amidst Phase III Results of PovorcitinibNews and Statistics - IndexBox, Inc.

Mar 17, 2025
pulisher
Mar 17, 2025

Top Stock Movers Now: Intel, Netflix, Incyte, and More - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Incyte Is Today’s Worst S&P 500 Stock. Here’s Why. - MSN

Mar 17, 2025

Incyte Corp (INCY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):